Evidence map›Paper›PMID 31673363›Full record

ArticleBMJ open respiratory research2019

Prevalence and outcome of central airway obstruction in patients with lung cancer.

Cyrus Daneshvar, William Euan Falconer, Mohammed Ahmed, Abdul Sibly, Madeleine Hindle, Thomas W Nicholson, Ghanem Aldik, Lilanganee A Telisinghe, Richard D Riordan, Adrian Marchbank and 1 more

Abstract read
In one paragraph

Article in BMJ open respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Interventional bronchoscopy in lung cancer treatment.Breathe (Sheffield, England) · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cyrus DaneshvarRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.ORCID 0000-0003-0956-8674
William Euan FalconerRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.
Mohammed AhmedInterventional Respiratory Unit, Galway University Hospitals, Galway, Ireland.ORCID 0000-0002-9921-2286
Abdul SiblyRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.
Madeleine HindleRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.
Thomas W NicholsonRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.
Ghanem AldikRespiratory Medicine, Plymouth Hospitals NHS Trust, Plymouth, UK.
Lilanganee A TelisingheDepartment of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
Richard D RiordanImaging, Plymouth Hospitals NHS Trust, Plymouth, UK.
Adrian MarchbankCardiothoracic Surgery, Plymouth Hospitals NHS Trust, Plymouth, UK.
David BreenRespiratory, Galway University Hospital, Galway, Ireland.

Funding

Medical Research Council MR/N020618/1
6 · The paper itself

Abstract

Introduction: Central airway obstruction (CAO) is a life-threatening complication of lung cancer. The prevalence of CAO in lung cancer patients is unknown. We audited CAO burden to inform our local cancer service. Methods: This is a cohort review of all new lung cancer diagnoses between 1 November 2014 and 30 November 2015. CAO was defined by CT appearance. CT scans and routine patient records were followed up to 30 November 2018 to determine the prevalence of CAO at diagnosis; the characteristics of patients with prevalent CAO; mortality (using survival analysis); and incident CAO over follow-up. Results: Of 342 new lung cancer diagnoses, CAO prevalence was 13% (95% CI 10% to 17%; n=45/342). Dedicated CT scan review identified missed CAO in 14/45 (31%) cases. In patients with prevalent CAO, 27/44 (61%) had a performance status of ≤2, 23/45 (51%) were diagnosed during an acute admission and 36/44 (82%) reported symptoms. Treatments were offered to 32/45 (71%); therapeutic bronchoscopy was performed in only 8/31 (26%) eligible patients. Median survival of patients with prevalent CAO was 94 (IQR 33-274) days. Multivariate analysis, adjusting for age, gender and disease stage, found CAO on index CT scan was independently associated with an increased hazard of death (adjusted HR 1.78 (95% CI 1.27 to 2.48); p=0.001). In total, 15/297 (5%) developed CAO during follow-up (median onset 340 (IQR 114-551) days). Over the audit period, 60/342 (18%; 95% CI 14% to 22%) had or developed CAO. Discussions: This is the first description of CAO prevalence in 40 years. Patients with prevalent CAO had a higher mortality. Our data provide a benchmark for service planning.

Indexed as

Cost of IllnessAgedAged, 80 and overAirway ObstructionBronchoscopyFemaleFollow-Up StudiesHumansIncidenceKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedPrevalenceUnited Kingdombronchoscopyclinical epidemiologyimaging/CT MRI etclung cancernon-small cell lung cancerpalliative caresmall cell lung cancerthoracic surgery

Identifiers

PMID31673363
PMCPMC6797367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.